These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 31933220)

  • 1.
    Groheux D; Hindié E
    Ann Surg Oncol; 2020 May; 27(5):1708-1709. PubMed ID: 31933220
    [No Abstract]   [Full Text] [Related]  

  • 2. Overuse of Preoperative Staging of Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
    Srour MK; Lee M; Walcott-Sapp S; Luu M; Chung A; Giuliano AE; Amersi F
    Ann Surg Oncol; 2019 Oct; 26(10):3289-3294. PubMed ID: 31342365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Letter to the Editor: "18FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher".
    Srour MK; Amersi F
    Ann Surg Oncol; 2020 May; 27(5):1710-1711. PubMed ID: 31907750
    [No Abstract]   [Full Text] [Related]  

  • 6. The Effect of FDG-PET/CT on Clinical Prognostic Staging of Breast Cancer Patients being Planned Neoadjuvant Treatment.
    Simsek ET; Coban E; Atag E; Gungor S; Aker F; Sari M
    J Coll Physicians Surg Pak; 2022 Feb; 32(2):181-185. PubMed ID: 35108788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Near-Infrared Diffuse Optical Imaging and 18F-FDG PET/CT for the Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy.
    Jiang S; Pogue BW
    J Nucl Med; 2016 Aug; 57(8):1166-7. PubMed ID: 27103023
    [No Abstract]   [Full Text] [Related]  

  • 8. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
    Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
    Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of FDG PET/CT in the clinical management of breast cancer.
    Groheux D; Espié M; Giacchetti S; Hindié E
    Radiology; 2013 Feb; 266(2):388-405. PubMed ID: 23220901
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.
    Pahk K; Rhee S; Cho J; Seo M; Lee S; Park T; Park S; Lee E; Park KH; Kim C; Eo JS; Kim S; Choe JG
    Anticancer Res; 2014 Aug; 34(8):4447-55. PubMed ID: 25075084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
    Lin CY; Lin CL; Kao CH
    Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis.
    Mghanga FP; Lan X; Bakari KH; Li C; Zhang Y
    Clin Breast Cancer; 2013 Aug; 13(4):271-9. PubMed ID: 23714689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.